{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:33:45Z","timestamp":1793738025474,"version":"4.6.1"},"reference-count":33,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,10,23]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>Diagnosis and management of status epilepticus (SE), including non-convulsive status epilepticus (NCSE), is challenging, with a reported 30%\u201350% of epilepticus patients not responding to available antiseizure medications (ASMs). Injectable benzodiazepines, fosphenytoin, valproate, levetiracetam, lacosamide and phenobarbital are commonly used for treating SE. Brivaracetam, a new ASM, with higher affinity and greater selectivity for the synaptic vesicle glycoprotein 2A than levetiracetam, has been approved as monotherapy or adjunct for treatment of focal onset seizures. Brivaracetam may have a role in the management of SE. However, limited data exist on brivaracetam\u2019s efficacy in SE. We describe a patient case with focal NCSE refractory to levetiracetam, fosphenytoin, lacosamide and valproate who demonstrated clinical and electrographic improvement on continuous electroencephalography monitoring after brivaracetam administration.<\/jats:p>","DOI":"10.1136\/bcr-2020-234955","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T16:03:12Z","timestamp":1606147392000},"page":"e234955","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Intravenous brivaracetam for the management of refractory focal non-convulsive status epilepticus"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1427-1173","authenticated-orcid":false,"given":"Abdalla A","family":"Ammar","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Yale New Haven Health System, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3401-9960","authenticated-orcid":false,"given":"Mahmoud A","family":"Ammar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yale New Haven Health System, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Owusu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yale New Haven Health System, New Haven, Connecticut, USA"},{"name":"Clinical Redesign, Yale New Haven Health System, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J","family":"Gilmore","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neurocritical Care and Emergency Neurology, Division of Epilepsy, Yale New Haven Health System, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"2025082708092836000_13.11.e234955.1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13121"},{"key":"2025082708092836000_13.11.e234955.2","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.12688\/f1000research.10939.1","article-title":"Novel clinical features of nonconvulsive status epilepticus","volume":"6","author":"Nagayama","year":"2017","journal-title":"F1000Res"},{"key":"2025082708092836000_13.11.e234955.3","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-012-9711-3"},{"key":"2025082708092836000_13.11.e234955.4","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-012-9790-1"},{"key":"2025082708092836000_13.11.e234955.5","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/epi.14016","article-title":"Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions","volume":"59","author":"Hirsch","year":"2018","journal-title":"Epilepsia"},{"key":"2025082708092836000_13.11.e234955.6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-Based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"2025082708092836000_13.11.e234955.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02917.x"},{"key":"2025082708092836000_13.11.e234955.8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182563b19"},{"key":"2025082708092836000_13.11.e234955.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200002033420503"},{"key":"2025082708092836000_13.11.e234955.10","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","article-title":"Randomized trial of three anticonvulsant medications for status epilepticus","volume":"381","author":"Kapur","year":"2019","journal-title":"N Engl J Med"},{"key":"2025082708092836000_13.11.e234955.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03330350028021"},{"key":"2025082708092836000_13.11.e234955.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809173391202"},{"key":"2025082708092836000_13.11.e234955.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804023381407"},{"key":"2025082708092836000_13.11.e234955.14","doi-asserted-by":"publisher","DOI":"10.1177\/0897190010372321"},{"key":"2025082708092836000_13.11.e234955.15","unstructured":"Phenytoin sodium injection [package insert]. Eatontown, NJ: West-Ward, A Hikma Company 2017."},{"key":"2025082708092836000_13.11.e234955.16","unstructured":"Fosphenytoin sodium injection [package insert]. Rockford, IL: Mylan Ins titutional LLC 2019."},{"key":"2025082708092836000_13.11.e234955.17","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1212\/WNL.40.6.990","article-title":"Lorazepam treatment of experimental status epilepticus in the rat: relevance to clinical practice","volume":"40","author":"Walton","year":"1990","journal-title":"Neurology"},{"key":"2025082708092836000_13.11.e234955.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(98)01080-4"},{"key":"2025082708092836000_13.11.e234955.19","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-009-9185-0"},{"key":"2025082708092836000_13.11.e234955.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2008.01.004"},{"key":"2025082708092836000_13.11.e234955.21","unstructured":"Keppra injection [package insert]. Smyrna, GA: UCB Inc 2019."},{"key":"2025082708092836000_13.11.e234955.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.04.064"},{"key":"2025082708092836000_13.11.e234955.23","unstructured":"Briviact [package insert]. Smyrna, GA: UCB Inc 2018."},{"key":"2025082708092836000_13.11.e234955.24","first-page":"1","article-title":"A review of the pharmacology and clinical efficacy of brivaracetam","volume":"10","author":"Klein","year":"2018","journal-title":"Clin Pharmacol"},{"key":"2025082708092836000_13.11.e234955.25","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13340"},{"key":"2025082708092836000_13.11.e234955.26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/epi.13267","article-title":"Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action","volume":"57","author":"Nicolas","year":"2016","journal-title":"Epilepsia"},{"key":"2025082708092836000_13.11.e234955.27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.yebeh.2017.03.028","article-title":"Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals","volume":"70","author":"Strzelczyk","year":"2017","journal-title":"Epilepsy Behav"},{"key":"2025082708092836000_13.11.e234955.28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/epi.14486","article-title":"Intravenous brivaracetam in status epilepticus: a retrospective single-center study","volume":"59","author":"Kalss","year":"2018","journal-title":"Epilepsia"},{"key":"2025082708092836000_13.11.e234955.29","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/epi.16094","article-title":"Use of intravenous brivaracetam in status epilepticus: a multicenter registry","volume":"60","author":"Santamarina","year":"2019","journal-title":"Epilepsia"},{"key":"2025082708092836000_13.11.e234955.30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eplepsyres.2018.12.001","article-title":"Intravenous brivaracetam in status epilepticus: correlation between loading dose, plasma levels and clinical response","volume":"149","author":"Aicua-Rapun","year":"2019","journal-title":"Epilepsy Res"},{"key":"2025082708092836000_13.11.e234955.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.11.004"},{"key":"2025082708092836000_13.11.e234955.32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/phar.2231","article-title":"Augmented renal clearance","volume":"39","author":"Cook","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2025082708092836000_13.11.e234955.33","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1592\/phco.31.10.934","article-title":"Steady-State pharmacokinetics of intravenous levetiracetam in neurocritical care patients","volume":"31","author":"Spencer","year":"2011","journal-title":"Pharmacotherapy"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-234955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:09:36Z","timestamp":1756307376000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-234955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,23]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/bcr-2020-234955"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-234955","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}